Sotorasib Shows Intracranial Activity in Patients with KRAS G12C- Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases
Treatment with sotorasib has shown intracranial complete responses and continued intracranial stabilization in KRAS G12C-mutated non-small-cell lung carcinoma (NSCLC) patients with previously treated, stable brain metastases in a post hoc analysis of the ongoing CodeBreaK 100 trial. We present the case of a patient with KRAS G12C-mutant adenocarcinoma of the lung with active untreated brain metastases with a nearly complete intracranial response only 6 weeks after start of sotorasib illustrating the benefit of sotorasib in patients with active, previously untreated brain metastases in KRAS G12C-mutated NSCLC.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Sotorasib Shows Intracranial Activity in Patients with KRAS G12C- Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases ; volume:15 ; number:2 ; year:2022 ; pages:720-725 ; extent:6
Case reports in oncology ; 15, Heft 2 (2022), 720-725 (gesamt 6)
- Urheber
-
Koster, Kira-Lee
Appenzeller, Christina
Lauber, Arno
Früh, Martin
Schmid, Sabine
- DOI
-
10.1159/000525341
- URN
-
urn:nbn:de:101:1-2022092200431270028757
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Koster, Kira-Lee
- Appenzeller, Christina
- Lauber, Arno
- Früh, Martin
- Schmid, Sabine
Ähnliche Objekte (12)
Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines
CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma
Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk
Assessment of intracranial metastases from neuroendocrine tumors/carcinoma
Regulation and therapeutic targeting of MTHFD2 and EZH2 in KRAS mutated human pulmonary adenocarcinoma
Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines
CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma
Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk
Assessment of intracranial metastases from neuroendocrine tumors/carcinoma
Regulation and therapeutic targeting of MTHFD2 and EZH2 in KRAS mutated human pulmonary adenocarcinoma
Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines
CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma
Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk
Assessment of intracranial metastases from neuroendocrine tumors/carcinoma